New York Medicaid and tirzepatide
Zepbound for weight loss: no. Drug list row: obstructive sleep apnea with BMI of 40 or higher, lifestyle changes, two treatment attempts per lifetime. Mounjaro for weight loss: no; for type 2 diabetes New York Medicaid must cover it. Read from New York State Department of Health documents Nov 6, 2026.
Zepbound · New York State Department of Health, NYRx
“Eli Lilly and Company Drugs indicated for weight loss are not covered pursuant to SSA §1927(d)(2)”
read Nov 6, 2026
Zepbound · New York State Department of Health, NYRx
“Confirm diagnosis of obstructive sleep apnea (OSA)”
read Nov 6, 2026
In 2025 New York Medicaid paid for 218,875 tirzepatide prescriptions (Mounjaro, Zepbound), 27% of its GLP-1 prescriptions and 5th of the 50 states and DC. It reimbursed $232.3 million before rebates, $1,062 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Mounjaro | 218,864 | $232.3 million | $1,062 |
| Zepbound | 11 | $1,041 | $95 |
New York plans and prescribing rules
Empire Plan (NYSHIP). The Empire Plan's January 2026 Advanced Flexible Formulary lists Wegovy and Zepbound as preferred anti-obesity agents, each requiring prior authorization.
Tirzepatide in the states around New York
| State | Sell tirzepatide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Zepbound for weight loss |
|---|---|---|---|---|
| New York | 17 | $69/moWellmedr | 218,875 | Medicaid Zepbound: No |
| Connecticut | 17 | $69/moWellmedr | 53,677 | Medicaid Zepbound: No |
| Massachusetts | 16 | $69/moWellmedr | 269,389 | Medicaid Zepbound: No |
| New Jersey | 17 | $69/moWellmedr | 44,265 | Medicaid Zepbound: Not covered (KFF) |
| Pennsylvania | 17 | $69/moWellmedr | 243,243 | Medicaid Zepbound: No |
| Vermont | 17 | $69/moWellmedr | 2,783 | Medicaid Zepbound: No |



